Resumé
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
| Originalsprog | Engelsk |
|---|---|
| Publikationsdato | 10. maj 2014 |
| Antal sider | 3 |
| DOI | |
| Status | Udgivet - 10. maj 2014 |
| Begivenhed | 24th European Congress of Clinical Microbiology and Infectious Diseases - Barcelona, Spanien Varighed: 10. maj 2014 → 13. maj 2014 Konferencens nummer: 24 |
Konference
| Konference | 24th European Congress of Clinical Microbiology and Infectious Diseases |
|---|---|
| Nummer | 24 |
| Land | Spanien |
| By | Barcelona |
| Periode | 10/05/2014 → 13/05/2014 |
Fingeraftryk
Citer dette
}
Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei. / Jensen, Rasmus Hare; Justesen, Ulrik Stenz; Rewes, Annika; Perlin, David S; Arendrup, Maiken Cavling.
2014. Abstract fra 24th European Congress of Clinical Microbiology and Infectious Diseases , Barcelona, Spanien.Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review
TY - ABST
T1 - Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei
AU - Jensen, Rasmus Hare
AU - Justesen, Ulrik Stenz
AU - Rewes, Annika
AU - Perlin, David S
AU - Arendrup, Maiken Cavling
N1 - Copyright © 2014, American Society for Microbiology. All Rights Reserved.
PY - 2014/5/10
Y1 - 2014/5/10
N2 - Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
AB - Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
U2 - 10.1128/AAC.02367-14
DO - 10.1128/AAC.02367-14
M3 - Conference abstract for conference
ER -